Immunotherapy: Checkpoint parley

Nature Reviews Cancer

Volumn 15, Issue 1, 2015, Pages 3-

  Bordon, Yvonne ^a  

^a Nature Reviews Immunology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BIOLOGICAL MARKER; CANCER VACCINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IPILIMUMAB; MPDL 3280A; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; TICILIMUMAB;

BLADDER CANCER; CANCER CHEMOTHERAPY; CD8+ T LYMPHOCYTE; DISEASE CLEARANCE; EXOME; GENE MUTATION; GENE SEQUENCE; KIDNEY CARCINOMA; MASS SPECTROMETRY; MELANOMA; METASTATIC MELANOMA; NON SMALL CELL LUNG CANCER; NONHUMAN; NOTE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOMA; SOLID TUMOR; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

EID: 84927103342     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3880     Document Type: Note

References (7)

1. Herbst, R. S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563-567 (2014)
2. Powles, T. et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515, 558-562 (2014)
3. Robert, C. et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1412082 (2014)
4. Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568-571 (2014)
5. Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1406498 (2014)
6. Yadav, M. et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 515, 572-576 (2014)
7. Gubin, M. M. et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515, 577-581 (2014)